World Seeking Shot In The Arm For Vaccine Production ibtimes.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ibtimes.com.au Daily Mail and Mail on Sunday newspapers.
Getty Images
On 30 March, 25 heads of state including South Africa’s President Cyril Ramaphosa called for the creation of an international pandemic treaty through the World Health Organization (WHO) to strengthen global capacity to predict and respond to pandemic threats. The call was published as a commentary in newspapers across the world.
Those endorsing the commentary include leaders of both developed and developing countries – such as Germany, the United Kingdom, South Korea, South Africa, and Senegal.
The commentary was also signed by the WHO Director-General Dr Tedros Adhanom Ghebreyesus and the EU President Charles Michel.
Ellen tHoen, an expert on medicines policy and law, told
Pfizer and Moderna shots, based on mRNA technology, mostly have served wealthy nations. AstraZeneca and Johnson & Johnson vaccines are expected to fill the global gap.
Rare side effects cast cloud over vaccines much of the world desperately needs Christopher Rowland A doctor fills a syringe with the Indian version of the AstraZeneca coronavirus vaccine at a hospital in Kabul on Monday. (Rahmat Gul/AP) Concerns about blood clots associated with the AstraZeneca and Johnson & Johnson coronavirus vaccines are deepening worries that the shots may not soon reach developing nations, which are far behind rich countries in immunizations and lack widespread access to costlier alternatives. The rollout of the Pfizer and Moderna vaccines this year generated a surge of optimism in the United States and helped President Biden reap the political rewards of an accelerating schedule of immunizations.
BusinessWorld
By Teodoro B. Padilla
Thomas B. Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), emphasized that vaccine makers are fully committed to transparency in reporting clinical trial results. They likewise support the need to inform the public of what they know, as well as what they donât know about the vaccines in development.
âWe must prioritize thorough validation of the results of pre-clinical and clinical trials by independent expert bodies. Only the most rigorous application of science and openness in the regulatory process can ensure that everyone, starting with healthcare workers, has confidence in COVID-19 vaccines once they have been properly approved,â he wrote in an opinion piece (